$SPRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GUIDED THERAPEUTICS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in GUIDED THERAPEUTICS INC. Get notifications about new insider transactions in GUIDED THERAPEUTICS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | M | 0.39 | 20,000 | 7,800 | 0 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | M | 0.33 | 20,000 | 6,600 | 0 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | A | 0.39 | 20,000 | 7,800 | 20,000 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 157,787 | 102,562 | 2,622,147 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 2,464,360 | 1,601,834 | 2,464,360 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 38,462 | 25,000 | 38,462 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | A | 0.33 | 20,000 | 6,600 | 20,000 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 383,330 | 249,165 | 383,330 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 85,185 | 55,370 | 85,185 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 170,369 | 110,740 | 170,369 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Option Exercise | P | 0.65 | 170,369 | 110,740 | 0 | |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Grant | A | 0.00 | 22,500 | 0 | 5,964,257 | 5.9 M to 6 M (+0.38 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | J | 0.65 | 1,059,716 | 688,815 | 5,941,757 | 4.9 M to 5.9 M (+21.71 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | J | 0.65 | 767,077 | 498,600 | 4,882,041 | 4.1 M to 4.9 M (+18.64 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | J | 0.65 | 997,247 | 648,211 | 4,114,964 | 3.1 M to 4.1 M (+31.99 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | M | 0.39 | 20,000 | 7,800 | 3,117,717 | 3.1 M to 3.1 M (+0.65 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | M | 0.33 | 20,000 | 6,600 | 3,097,717 | 3.1 M to 3.1 M (+0.65 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | P | 0.20 | 581,329 | 116,266 | 3,077,717 | 2.5 M to 3.1 M (+23.29 %) |
| Jun 09 2011 | SPRX | GUIDED THERAPEUTIC ... | Imhoff John E | Director | Buy | P | 0.35 | 1,872,838 | 655,493 | 2,496,388 | 623.6 K to 2.5 M (+300.35 %) |
| May 25 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.95 | 12,500 | 11,875 | 1,175,868 | 1.2 M to 1.2 M (-1.05 %) |
| May 25 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.98 | 2,500 | 2,450 | 1,188,368 | 1.2 M to 1.2 M (-0.21 %) |
| May 25 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.99 | 10,000 | 9,900 | 1,190,868 | 1.2 M to 1.2 M (-0.83 %) |
| May 16 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Grant | A | 0.30 | 5,000 | 1,500 | 15,399 | 20.4 K to 15.4 K (-24.51 %) |
| May 16 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Sell | D | 1.00 | 5,000 | 5,000 | 10,399 | 15.4 K to 10.4 K (-32.47 %) |
| May 11 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.03 | 3,100 | 3,193 | 1,200,868 | 1.2 M to 1.2 M (-0.26 %) |
| May 11 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.04 | 9,400 | 9,776 | 1,203,968 | 1.2 M to 1.2 M (-0.77 %) |
| May 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.08 | 2,000 | 2,160 | 1,213,368 | 1.2 M to 1.2 M (-0.16 %) |
| May 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.05 | 1,800 | 1,890 | 1,215,368 | 1.2 M to 1.2 M (-0.15 %) |
| May 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.03 | 8,700 | 8,961 | 1,217,168 | 1.2 M to 1.2 M (-0.71 %) |
| Apr 29 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Grant | A | 0.30 | 5,000 | 1,500 | 15,399 | 20.4 K to 15.4 K (-24.51 %) |
| Apr 29 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Sell | D | 1.00 | 5,000 | 5,000 | 10,399 | 15.4 K to 10.4 K (-32.47 %) |
| Apr 26 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.90 | 12,500 | 11,250 | 1,225,868 | 1.2 M to 1.2 M (-1.01 %) |
| Apr 21 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.89 | 2,100 | 1,869 | 1,238,368 | 1.2 M to 1.2 M (-0.17 %) |
| Apr 21 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.90 | 10,400 | 9,360 | 1,240,468 | 1.3 M to 1.2 M (-0.83 %) |
| Apr 15 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.91 | 2,500 | 2,275 | 1,250,868 | 1.3 M to 1.3 M (-0.20 %) |
| Apr 15 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.90 | 10,000 | 9,000 | 1,253,368 | 1.3 M to 1.3 M (-0.79 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.93 | 12,500 | 11,625 | 1,263,368 | 1.3 M to 1.3 M (-0.98 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.91 | 2,500 | 2,275 | 1,275,868 | 1.3 M to 1.3 M (-0.20 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.93 | 1,900 | 1,767 | 1,278,368 | 1.3 M to 1.3 M (-0.15 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.93 | 100 | 93 | 1,280,268 | 1.3 M to 1.3 M (-0.01 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.92 | 2,000 | 1,840 | 1,280,368 | 1.3 M to 1.3 M (-0.16 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.91 | 1,000 | 910 | 1,282,368 | 1.3 M to 1.3 M (-0.08 %) |
| Apr 05 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.90 | 5,000 | 4,500 | 1,283,368 | 1.3 M to 1.3 M (-0.39 %) |
| Mar 14 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Grant | A | 0.30 | 5,000 | 1,500 | 15,399 | 20.4 K to 15.4 K (-24.51 %) |
| Mar 14 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Sell | D | 1.35 | 5,000 | 6,750 | 10,399 | 15.4 K to 10.4 K (-32.47 %) |
| Feb 25 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.40 | 12,500 | 17,500 | 1,338,368 | 1.4 M to 1.3 M (-0.93 %) |
| Mar 21 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.00 | 10,000 | 10,000 | 1,288,368 | 1.3 M to 1.3 M (-0.77 %) |
| Mar 21 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.90 | 2,500 | 2,250 | 1,298,368 | 1.3 M to 1.3 M (-0.19 %) |
| Mar 21 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.90 | 5,000 | 4,500 | 1,300,868 | 1.3 M to 1.3 M (-0.38 %) |
| Mar 21 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 0.88 | 7,500 | 6,600 | 1,305,868 | 1.3 M to 1.3 M (-0.57 %) |
| Mar 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.20 | 8,600 | 10,320 | 1,313,368 | 1.3 M to 1.3 M (-0.65 %) |
| Mar 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.21 | 3,900 | 4,719 | 1,321,968 | 1.3 M to 1.3 M (-0.29 %) |
| Mar 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.30 | 3,000 | 3,900 | 1,325,868 | 1.3 M to 1.3 M (-0.23 %) |
| Mar 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.25 | 500 | 625 | 1,328,868 | 1.3 M to 1.3 M (-0.04 %) |
| Mar 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.23 | 9,000 | 11,070 | 1,329,368 | 1.3 M to 1.3 M (-0.67 %) |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.35 | 2,500 | 3,375 | 1,367,868 | 1.4 M to 1.4 M (-0.18 %) |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.30 | 2,500 | 3,250 | 1,370,368 | 1.4 M to 1.4 M (-0.18 %) |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.32 | 2,500 | 3,300 | 1,372,868 | 1.4 M to 1.4 M (-0.18 %) |
| Feb 17 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.36 | 2,000 | 2,720 | 1,350,868 | 1.4 M to 1.4 M (-0.15 %) |
| Feb 17 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.38 | 5,500 | 7,590 | 1,352,868 | 1.4 M to 1.4 M (-0.40 %) |
| Feb 17 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.39 | 1,000 | 1,390 | 1,358,368 | 1.4 M to 1.4 M (-0.07 %) |
| Feb 17 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.40 | 1,500 | 2,100 | 1,359,368 | 1.4 M to 1.4 M (-0.11 %) |
| Feb 15 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.34 | 2,500 | 3,350 | 1,360,868 | 1.4 M to 1.4 M (-0.18 %) |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | M | 0.00 | 20,000 | 0 | 898,750 | |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | M | 0.00 | 500,000 | 0 | 398,750 | |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | M | 0.25 | 100,000 | 25,000 | 298,750 | |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Buy | M | 0.00 | 20,000 | 0 | 257,487 | 237.5 K to 257.5 K (+8.42 %) |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Buy | M | 0.00 | 500,000 | 0 | 757,487 | 257.5 K to 757.5 K (+194.18 %) |
| Feb 11 2011 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Buy | M | 0.25 | 100,000 | 25,000 | 857,487 | 757.5 K to 857.5 K (+13.20 %) |
| Feb 10 2011 | SPRX | GUIDED THERAPEUTIC ... | FAUPEL MARK L | President,CEO, & Ac ... | Option Exercise | A | 1.00 | 400,000 | 400,000 | 2,006,000 | |
| Feb 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.25 | 2,500 | 3,125 | 1,370,868 | 1.4 M to 1.4 M (-0.18 %) |
| Feb 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.44 | 2,000 | 2,880 | 1,373,368 | 1.4 M to 1.4 M (-0.15 %) |
| Feb 09 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.45 | 500 | 725 | 1,375,368 | 1.4 M to 1.4 M (-0.04 %) |
| Feb 03 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Grant | A | 0.30 | 5,000 | 1,500 | 15,399 | 20.4 K to 15.4 K (-24.51 %) |
| Feb 03 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Sell | D | 1.08 | 5,000 | 5,400 | 10,399 | 15.4 K to 10.4 K (-32.47 %) |
| Jan 31 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.15 | 9,100 | 10,465 | 1,375,868 | 1.4 M to 1.4 M (-0.66 %) |
| Jan 31 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.17 | 900 | 1,053 | 1,384,968 | 1.4 M to 1.4 M (-0.06 %) |
| Jan 31 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.18 | 500 | 590 | 1,385,868 | 1.4 M to 1.4 M (-0.04 %) |
| Jan 31 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | D | 1.19 | 2,000 | 2,380 | 1,386,368 | 1.4 M to 1.4 M (-0.14 %) |
| Jan 28 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Sell | D | 1.03 | 5,000 | 5,150 | 15,399 | 20.4 K to 15.4 K (-24.51 %) |
| Jan 28 2011 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. R & D | Sell | D | 1.00 | 5,000 | 5,000 | 10,399 | 15.4 K to 10.4 K (-32.47 %) |
| Jan 27 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.96 | 6,000 | 5,760 | 1,388,368 | 1.4 M to 1.4 M (-0.43 %) |
| Jan 27 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 1.00 | 4,000 | 4,000 | 1,394,368 | 1.4 M to 1.4 M (-0.29 %) |
| Jan 27 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.97 | 2,500 | 2,425 | 1,398,368 | 1.4 M to 1.4 M (-0.18 %) |
| Jan 19 2011 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 1.00 | 12,500 | 12,500 | 1,400,868 | 1.4 M to 1.4 M (-0.88 %) |
| Dec 28 2010 | SPRX | GUIDED THERAPEUTIC ... | FAUPEL MARK L | President,CEO, & Ac ... | Grant | A | 0.82 | 100,000 | 82,000 | 100,000 | 0 to 100 K |
| Dec 21 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.80 | 12,500 | 10,000 | 1,413,368 | 1.4 M to 1.4 M (-0.88 %) |
| Dec 15 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.82 | 5,115 | 4,194 | 1,444,868 | 1.4 M to 1.4 M (-0.35 %) |
| Dec 16 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.79 | 19,000 | 15,059 | 1,425,868 | 1.4 M to 1.4 M (-1.31 %) |
| Dec 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.82 | 2,500 | 2,050 | 1,449,983 | 1.5 M to 1.4 M (-0.17 %) |
| Dec 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.82 | 12,500 | 10,250 | 1,452,483 | 1.5 M to 1.5 M (-0.85 %) |
| Nov 23 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.81 | 20,000 | 16,200 | 26,250 | 46.3 K to 26.3 K (-43.24 %) |
| Nov 23 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.80 | 20,000 | 16,000 | 46,250 | 66.3 K to 46.3 K (-30.19 %) |
| Nov 23 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.80 | 25,000 | 20,000 | 66,250 | 91.3 K to 66.3 K (-27.40 %) |
| Nov 30 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Sell | S | 0.81 | 22,253 | 18,025 | 1,464,983 | 1.5 M to 1.5 M (-1.50 %) |
| Jun 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | P | 0.65 | 1,736,574 | 1,128,773 | 1,736,574 | |
| Jun 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | H | 0.78 | 1,736,574 | 1,354,528 | 0 | |
| Jun 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Buy | C | 0.65 | 1,487,236 | 966,703 | 1,487,236 | 0 to 1.5 M |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | ALLEN RONALD W | Director | Option Exercise | A | 0.98 | 20,000 | 19,600 | 542,500 | |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | ALLEN RONALD W | Director | Buy | C | 0.00 | 22,500 | 0 | 22,500 | 0 to 22.5 K |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | ZACHARY WILLIAM E JR | Director | Option Exercise | A | 0.98 | 25,000 | 24,500 | 296,000 | |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | ZACHARY WILLIAM E JR | Director | Buy | C | 0.00 | 25,000 | 0 | 37,963 | 13 K to 38 K (+192.86 %) |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.98 | 26,250 | 25,725 | 1,911,286 | |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Buy | C | 0.00 | 26,250 | 0 | 1,956,286 | 1.9 M to 2 M (+1.36 %) |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | A | 0.98 | 23,750 | 23,275 | 1,351,442 | |
| Apr 01 2010 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Buy | C | 0.00 | 23,750 | 0 | 23,750 | 0 to 23.8 K |
| Mar 17 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.39 | 20,000 | 7,800 | 1,885,036 | |
| Mar 17 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.39 | 25,000 | 9,750 | 1,910,036 | |
| Mar 17 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.33 | 20,000 | 6,600 | 1,930,036 | |
| Mar 17 2010 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Buy | C | 0.00 | 65,000 | 0 | 1,930,036 | 1.9 M to 1.9 M (+3.49 %) |
| May 29 2009 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.39 | 20,000 | 7,800 | 1,930,036 | |
| May 29 2009 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.39 | 25,000 | 9,750 | 1,910,036 | |
| May 27 2009 | SPRX | GUIDED THERAPEUTIC ... | ZACHARY WILLIAM E JR | Director | Option Exercise | A | 0.39 | 20,000 | 7,800 | 271,000 | |
| May 27 2009 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | A | 0.39 | 20,000 | 7,800 | 1,327,692 | |
| May 27 2009 | SPRX | GUIDED THERAPEUTIC ... | ALLEN RONALD W | Director | Option Exercise | A | 0.39 | 20,000 | 7,800 | 520,000 | |
| Jan 16 2009 | SPRX | GUIDED THERAPEUTIC ... | FAUPEL MARK L | CEO and President | Option Exercise | A | 0.38 | 1,000,000 | 380,000 | 1,170,000 | |
| Dec 16 2008 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | VP of R&D | Option Exercise | A | 0.33 | 260,000 | 85,800 | 688,000 | |
| May 16 2008 | SPRX | GUIDED THERAPEUTIC ... | JAMES MICHAEL C | Director | Option Exercise | A | 0.33 | 20,000 | 6,600 | 1,885,036 | |
| May 16 2008 | SPRX | GUIDED THERAPEUTIC ... | ZACHARY WILLIAM E JR | Director | Option Exercise | A | 0.33 | 20,000 | 6,600 | 251,000 | |
| May 16 2008 | SPRX | GUIDED THERAPEUTIC ... | ZACHARY WILLIAM E JR | Director | Option Exercise | A | 0.33 | 150,000 | 49,500 | 231,000 | |
| Feb 28 2008 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | A | 0.00 | 500,000 | 0 | 1,307,692 | |
| Nov 14 2007 | SPRX | GUIDED THERAPEUTIC ... | FOWLER RICHARD | Senior VP of Engine ... | Option Exercise | A | 0.30 | 300,000 | 90,000 | 537,240 | |
| Dec 17 2007 | SPRX | GUIDED THERAPEUTIC ... | HART RONALD W | Director | Option Exercise | A | 0.25 | 500,000 | 125,000 | 807,692 | |
| Nov 14 2007 | SPRX | GUIDED THERAPEUTIC ... | Bambot Shabbir Bakir | V.P. of R & D | Option Exercise | A | 0.30 | 400,000 | 120,000 | 431,000 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | ARTHUR WILLIAM D III | Secretary | Option Exercise | P | 0.78 | 56,120 | 43,774 | 523,240 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | ARTHUR WILLIAM D III | Secretary | Option Exercise | P | 0.65 | 56,120 | 36,478 | 467,120 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | FOWLER RICHARD | Senior VP of Engine ... | Option Exercise | P | 0.78 | 56,120 | 43,774 | 237,240 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | FOWLER RICHARD | Senior VP of Engine ... | Option Exercise | P | 0.65 | 56,120 | 36,478 | 181,120 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | SAMUELS MARK A | CEO & CFO | Option Exercise | P | 0.78 | 56,122 | 43,775 | 711,433 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | SAMUELS MARK A | CEO & CFO | Option Exercise | P | 0.65 | 56,122 | 36,479 | 655,311 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | SAMUELS MARK A | CEO & CFO | Option Exercise | P | 0.81 | 33,335 | 27,001 | 599,189 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | ARTHUR WILLIAM D III | SECRETARY | Option Exercise | E | 0.26 | 150,000 | 39,000 | 411,000 | |
| May 01 2007 | SPRX | GUIDED THERAPEUTIC ... | FAUPEL MARK L | PRESIDENT & COO | Option Exercise | E | 0.26 | 15,000 | 3,900 | 225,000 | |
| Apr 30 2007 | SPRX | GUIDED THERAPEUTIC ... | SAMUELS MARK A | CEO & CFO | Option Exercise | E | 0.26 | 335,000 | 87,100 | 512,005 | |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Option Exercise | P | 1.50 | 4,760 | 7,140 | 1,419,472 | |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Option Exercise | P | 1.50 | 5,316 | 7,974 | 1,414,712 | |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Option Exercise | P | 1.50 | 29,592 | 44,388 | 1,409,396 | |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.22 | 10,950 | 2,409 | 1,696,522 | 1.7 M to 1.7 M (-0.64 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.21 | 2,900 | 609 | 1,707,472 | 1.7 M to 1.7 M (-0.17 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.21 | 17,100 | 3,591 | 1,710,372 | 1.7 M to 1.7 M (-0.99 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.22 | 3,650 | 803 | 1,727,472 | 1.7 M to 1.7 M (-0.21 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.22 | 21,350 | 4,697 | 1,731,122 | 1.8 M to 1.7 M (-1.22 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.22 | 700 | 154 | 1,752,472 | 1.8 M to 1.8 M (-0.04 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.22 | 4,300 | 946 | 1,753,172 | 1.8 M to 1.8 M (-0.24 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.21 | 3,550 | 746 | 1,757,472 | 1.8 M to 1.8 M (-0.20 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.21 | 21,450 | 4,505 | 1,761,022 | 1.8 M to 1.8 M (-1.20 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.30 | 8,150 | 2,445 | 1,782,472 | 1.8 M to 1.8 M (-0.46 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.30 | 1,350 | 405 | 1,790,622 | 1.8 M to 1.8 M (-0.08 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.31 | 10,000 | 3,100 | 1,791,972 | 1.8 M to 1.8 M (-0.55 %) |
| Mar 16 2007 | SPRX | GUIDED THERAPEUTIC ... | Musket David B | 10% Owner | Sell | S | 0.20 | 102,692 | 20,538 | 1,801,972 | 1.9 M to 1.8 M (-5.39 %) |